IL1RL1 and acute myeloid leukemia: As shown in Fig. 10A, B, a significant reduction in spleen and liver sizes and weights is observed on treatment with anti-murine ST2 Ab compared to the control group, indicating a significant decrease in leukemic burden, emphasizing the suppressive ability of anti-murine ST2 Ab in this aggressive epigenetic AML model.